Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88,559Revenue $M26,095Net Margin (%)4.5Z-Score2.2
Enterprise Value $M92,101EPS $1.0Operating Margin %7.9F-Score4
P/E(ttm))81.4Cash Flow Per Share $0Pre-tax Margin (%)4.5Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %4.7Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %-16.2Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-44.3ROA % (ttm)2.1Higher Current Ratio y-yN
Dividend Yield %4.0Insider Buy (3m)0ROE % (ttm)5.6Less Shares Outstanding y-yN
Payout Ratio %287Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDavid Dreman 2014-12-31 Reduce-0.51%$67.15 - $75.38
($71.66)
$ 70.07-2%Reduce -75.42%28,764
AZNGeorge Soros 2014-12-31 Sold Out -0.08%$67.15 - $75.38
($71.66)
$ 70.07-2%Sold Out0
AZNMario Gabelli 2014-12-31 Reduce-0.01%$67.15 - $75.38
($71.62)
$ 70.07-2%Reduce -52.51%19,900
AZNCharles Brandes 2014-09-30 Sold Out -0.35%$68.49 - $76.31
($73.2)
$ 70.07-4%Sold Out0
AZNJohn Hussman 2014-09-30 Reduce-0.29%$68.49 - $76.31
($73.2)
$ 70.07-4%Reduce -22.37%173,500
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 70.07-3%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 70.07-3%Sold Out0
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 70.07-3%New holding150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 70.07-3%New holding40,400
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 70.07-3%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 70.078%Add 714.29%228,000
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 70.078%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 70.078%Reduce -46.73%1,333,894
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 70.078%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 70.078%New holding95,518
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 70.0723%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 70.0723%Reduce -24.90%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 70.0723%Reduce -58.82%28,000
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 70.0728%Reduce -81.87%68,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 70.0728%Add 7.92%2,381,040
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$17310.41view

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
      Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
      Brandes International Equity Fund Q3 Commentary Dec 23 2014 
      Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
      A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 


      More From Other Websites
      Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog Mar 26 2015
      AstraZeneca joins Genomics England consortium Mar 26 2015
      4 Sector Leaders To Boost Your ISA Returns: AstraZeneca plc, Standard Chartered PLC, Bellway plc &... Mar 25 2015
      AstraZeneca and Daiichi Sankyo to jointly commercialise MOVANTIK in the US Mar 25 2015
      AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes Mar 25 2015
      Stocks to Cure What Ails on World TB Day - Analyst Blog Mar 24 2015
      AstraZeneca to Disclose Trial Data, but how Independent is its Review Panel? Mar 24 2015
      Foreign investors buy UK firms at fastest pace since 2007 Mar 24 2015
      Biogen Gains on Positive Alzheimer's Drug Interim Results - Analyst Blog Mar 23 2015
      Biogen downgrade, Pfizer rises Mar 23 2015
      How to make money from these four super trends Mar 23 2015
      Eminence Capital Downs Position in Valeant Pharmaceuticals Mar 23 2015
      AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog Mar 20 2015
      Isa income fund tips: Get a boost with funds that pay 4pc to 6pc income Mar 20 2015
      Should You Buy AstraZeneca plc, Reckitt Benckiser Group Plc Or Premier Foods Plc For Your 2015 ISA? Mar 20 2015
      FDA panel backs Glaxo asthma drug for adults, not adolescents Mar 19 2015
      AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog Mar 19 2015
      The Marijuana CARERS Act: What You Need To Know Mar 19 2015
      AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S. Mar 19 2015
      AstraZeneca signs deal to commercialise new drug with Daiichi Sankyo Mar 19 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK